Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licartin plus TACE versus TACE alone for unresectable hepatocellular carcinoma
ChiCTR-TNRC-12002921Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of licofelone in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: survival time, tumor response to treatment and 1 more. Started Feb 2009; status: completed.
02
Drugs
licofelone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TNRC-12002921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-12002921.